Genmab A/S (GMAB) Short Interest Ratio & Short Volume $20.80 -0.42 (-1.98%) As of 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Genmab A/S Short Interest DataGenmab A/S (GMAB) has a short interest of 1.38 million shares, representing 0.22% of the float (the number of shares available for trading by the public). This marks a -25.81% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.1, indicating that it would take 1.1 days of the average trading volume of 1.16 million shares to cover all short positions.Current Short Interest1,380,000 sharesPrevious Short Interest1,860,000 sharesChange Vs. Previous Month-25.81%Dollar Volume Sold Short$28.80 millionShort Interest Ratio1.1 Days to CoverLast Record DateDecember 31, 2024Outstanding Shares661,770,000 sharesFloat Size635,230,000 sharesShort Percent of Float0.22%Today's Trading Volume1,120,112 sharesAverage Trading Volume1,163,783 sharesToday's Volume Vs. Average96% Short Selling Genmab A/S? Sign up to receive the latest short interest report for Genmab A/S and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGMAB Short Interest Over TimeGMAB Days to Cover Over TimeGMAB Percentage of Float Shorted Over Time Genmab A/S Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/31/20241,380,000 shares $28.80 million -25.8%0.2%1.1 $20.87 12/15/20241,860,000 shares $37.52 million -7.9%0.3%1.5 $20.17 11/30/20242,020,000 shares $43.43 million -11.4%0.3%1.8 $21.50 11/15/20242,280,000 shares $46.95 million -2.6%0.4%2.1 $20.59 10/31/20242,340,000 shares $52.23 million +23.2%0.4%2.7 $22.32 10/15/20241,900,000 shares $44.04 million -15.9%0.3%2.6 $23.18 Get the Latest News and Ratings for GMAB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. 9/30/20242,260,000 shares $55.10 million +8.7%0.4%3.6 $24.38 9/15/20242,080,000 shares $55.95 million -2.4%0.3%3.6 $26.90 8/31/20242,130,000 shares $59.21 million -1.8%0.3%3.6 $27.80 8/15/20242,170,000 shares $59.05 million -26.7%0.3%3.6 $27.21 7/31/20242,960,000 shares $83.74 million +33.3%0.5%4.9 $28.29 7/15/20242,220,000 shares $58.92 million -3.5%0.3%3.9 $26.54 6/30/20242,300,000 shares $57.80 million -8.4%0.4%4.7 $25.13 6/15/20242,510,000 shares $65.74 million -12.5%0.4%5.2 $26.19 5/31/20242,870,000 shares $80.93 million -3.0%0.4%6.1 $28.20 5/15/20242,960,000 shares $89.45 million +7.6%0.5%5.7 $30.22 4/30/20242,750,000 shares $76.15 million +4.6%0.4%4.9 $27.69 4/15/20242,630,000 shares $77.61 million +9.6%0.4%4.6 $29.51 3/31/20242,400,000 shares $71.78 million +17.1%0.4%3.8 $29.91 3/15/20242,050,000 shares $61.38 million +10.2%0.3%3.3 $29.94 2/29/20241,860,000 shares $51.65 million -19.5%0.3%2.9 $27.77 2/15/20242,310,000 shares $65.21 million +12.7%0.4%3.7 $28.23 1/31/20242,050,000 shares $56.60 million +9.6%0.3%3.1 $27.61 1/15/20241,870,000 shares $59.11 million +7.5%N/A2.4 $31.61 12/31/20231,740,000 shares $55.40 million +8.8%N/A2.1 $31.84 12/15/20231,600,000 shares $49.38 million +8.1%N/A1.9 $30.86 11/30/20231,480,000 shares $46.78 million -3.3%N/A1.8 $31.61 11/15/20231,530,000 shares $48.52 million -15.9%N/A1.9 $31.71 10/31/20231,820,000 shares $51.69 million -22.6%0.3%2.6 $28.40 10/15/20232,350,000 shares $75.86 million -10.0%N/A3.6 $32.28 9/30/20232,610,000 shares $92.05 million -2.6%N/A5.3 $35.27 9/15/20232,680,000 shares $101.79 million -7.3%N/A5.4 $37.98 8/31/20232,890,000 shares $110.66 million -16.2%N/A6 $38.29 8/15/20233,450,000 shares $128.31 million -17.7%N/A7.3 $37.19 7/31/20234,190,000 shares $173.30 million +7.4%N/A8.7 $41.36 7/15/20233,900,000 shares $156.08 million +1.8%N/A8.9 $40.02 6/30/20233,830,000 shares $145.58 million +13.3%N/A9.5 $38.01 6/15/20233,380,000 shares $130.98 million -6.4%N/A8.8 $38.75 5/31/20233,610,000 shares $141.55 million +6.8%N/A8.9 $39.21 5/15/20233,380,000 shares $142.43 million -4.5%N/A7.2 $42.14 4/30/20233,540,000 shares $145.18 million +1.7%N/A7.6 $41.01 4/15/20233,480,000 shares $144.70 million +0.3%N/A7 $41.58 3/31/20233,470,000 shares $131.03 million +12.3%N/A6.7 $37.76 3/15/20233,090,000 shares $110.34 million +7.3%N/A5.6 $35.71 2/28/20232,880,000 shares $108.17 million -4.6%N/A4.6 $37.56 2/15/20233,020,000 shares $119.95 million +1.3%N/A4.9 $39.72 1/31/20232,980,000 shares $116.67 million -4.8%0.5%4.6 $39.15 1/15/20233,130,000 shares $125.70 million -4.9%N/A4.6 $40.16 12/30/20223,290,000 shares $139.43 million +2.5%N/A5 $42.38 12/15/20223,210,000 shares $143.68 million -13.7%N/A4.6 $44.76 11/30/20223,720,000 shares $173.09 million +8.1%N/A6.1 $46.53 11/15/20223,440,000 shares $148.26 million +0.3%N/A5.9 $43.10 10/31/20223,430,000 shares $132.09 million -5.0%N/A6 $38.51 10/15/20223,610,000 shares $131.77 million +0.8%N/A6 $36.50 9/30/20223,580,000 shares $115.03 million +12.6%N/A5.9 $32.13 9/15/20223,180,000 shares $115.82 million +8.5%N/A5.5 $36.42 8/31/20222,930,000 shares $103.99 million -19.7%N/A4.9 $35.49 8/15/20223,650,000 shares $135.93 million +37.2%N/A5.8 $37.24 7/31/20222,660,000 shares $94.75 million +15.7%N/A3.8 $35.62 7/15/20222,300,000 shares $78.91 million +1.8%N/A3.4 $34.31 6/30/20222,260,000 shares $73.43 million -8.9%N/A3.3 $32.49 6/15/20222,480,000 shares $68.65 million +3.8%N/A3.7 $27.68 5/31/20222,390,000 shares $72.30 million +4.4%N/A3.6 $30.25 5/15/20222,290,000 shares $67.14 million +30.1%N/A3.4 $29.32 4/30/20221,760,000 shares $61.92 million +9.3%N/A2.7 $35.18 4/15/20221,610,000 shares $59.17 million -5.3%N/A2.5 $36.75 3/31/20221,700,000 shares $61.51 million -21.7%N/A2.8 $36.18 3/15/20222,170,000 shares $72.72 million -8.4%N/A3.8 $33.51 2/28/20222,370,000 shares $79.30 million -19.9%N/A4 $33.46 2/15/20222,960,000 shares $100.34 million +1.7%N/A5.2 $33.90 1/31/20222,910,000 shares $99.17 million +26.5%N/A5.5 $34.08 1/15/20222,300,000 shares $82.11 million +4.1%N/A4.9 $35.70 12/31/20212,210,000 shares $87.43 million +6.3%N/A5.3 $39.56 12/15/20212,080,000 shares $75.92 million +8.3%N/A5.2 $36.50 11/30/20211,920,000 shares $73.96 million +34.3%N/A5.2 $38.52 11/15/20211,430,000 shares $58.87 million +12.6%N/A4 $41.17 10/29/20211,270,000 shares $56.69 million +1.6%N/A3.6 $44.64 10/15/20211,250,000 shares $55.54 million +15.7%N/A3.6 $44.43 9/30/20211,080,000 shares $47.20 million +1.9%N/A3 $43.70 9/15/20211,060,000 shares $45.43 million -10.9%N/A2.9 $42.86 8/31/20211,190,000 shares $56.39 million -26.1%N/A2.5 $47.39 8/13/20211,610,000 shares $74.98 million -4.2%N/A3.3 $46.57 7/30/20211,680,000 shares $75.70 million +3.1%N/A3.5 $45.06 7/15/20211,630,000 shares $70.29 million +14.8%N/A3.3 $43.12 6/30/20211,420,000 shares $57.98 million +54.5%N/A2.8 $40.83 6/15/2021918,900 shares $40.45 million +11.8%N/A1.8 $44.02 5/28/2021822,100 shares $33.39 million +7.5%N/A1.8 $40.62 5/14/2021764,800 shares $28.07 million +22.1%N/A1.3 $36.70 4/30/2021626,200 shares $23.34 million +53.5%N/A1.1 $37.28 4/15/2021408,000 shares $14.15 million -13.2%N/A0.7 $34.67 3/31/2021470,000 shares $14.91 million -36.6%N/A0.7 $31.73 3/15/2021741,700 shares $24.39 million +17.1%N/A1.2 $32.89 2/26/2021633,200 shares $21.33 million -36.7%N/A1.1 $33.68 2/12/20211,000,000 shares $41.02 million +133.6%N/A2 $41.02 1/29/2021428,000 shares $17.21 million -49.6%N/A0.9 $40.20 1/15/2021849,000 shares $37.46 million -2.2%N/A1.7 $44.12 12/31/2020867,700 shares $35.37 million +45.9%N/A2 $40.76 12/15/2020594,700 shares $23.26 million -21.2%N/A1.2 $39.11 11/30/2020755,100 shares $28.04 million -2.6%N/A1.4 $37.13 11/15/2020775,200 shares $28.08 million -41.7%N/A1.4 $36.22 10/30/20201,330,000 shares $45.67 million +8.1%N/A2.4 $34.34 10/15/20201,230,000 shares $46.73 million +13.9%N/A2.1 $37.99 9/30/20201,080,000 shares $39.54 million +64.6%N/A1.8 $36.61 9/15/2020656,300 shares $24.30 million -32.4%N/A1.1 $37.03 8/31/2020970,300 shares $36.64 million +32.1%N/A1.3 $37.76 8/14/2020734,600 shares $27.12 million +12.3%N/A0.9 $36.92 7/31/2020653,900 shares $22.36 million -46.8%N/A0.7 $34.19 7/15/20201,230,000 shares $44.32 million +38.3%N/A1.2 $36.03 6/30/2020889,500 shares $29.02 million +20.2%N/A0.9 $32.63 6/15/2020740,300 shares $23.03 million -12.0%N/A0.7 $31.11 5/29/2020840,800 shares $25.62 million -33.3%N/A1 $30.47 5/15/20201,260,000 shares $36.02 million +190.5%N/A1.7 $28.59 4/30/2020433,800 shares $10.55 million -51.1%N/A0.7 $24.33 4/15/2020887,300 shares $19.43 million +99.8%N/A1.8 $21.90 3/31/2020444,100 shares $10.66 million -12.0%N/A1 $24.00 3/13/2020504,600 shares $11.28 million -42.9%N/A1.3 $22.36 2/28/2020883,800 shares $16.26 million +67.2%N/A2.6 $18.40 2/14/2020528,600 shares $11.79 million -15.7%N/A1.6 $22.30 1/31/2020627,300 shares $15.06 million +28.6%N/A2.3 $24.00 GMAB Short Interest - Frequently Asked Questions What is Genmab A/S's current short interest? Short interest is the volume of Genmab A/S shares that have been sold short but have not yet been covered or closed out. As of December 31st, traders have sold 1,380,000 shares of GMAB short. 0.22% of Genmab A/S's shares are currently sold short. Learn More on Genmab A/S's current short interest. What is a good short interest ratio for Genmab A/S? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GMAB shares currently have a short interest ratio of 1.0. Learn More on Genmab A/S's short interest ratio. What is a good short interest percentage for Genmab A/S? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.22% of Genmab A/S's floating shares are currently sold short. Is Genmab A/S's short interest increasing or decreasing? Genmab A/S saw a decline in short interest in December. As of December 31st, there was short interest totaling 1,380,000 shares, a decline of 25.8% from the previous total of 1,860,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Genmab A/S's float size? Genmab A/S currently has issued a total of 661,770,000 shares. Some of Genmab A/S's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Genmab A/S currently has a public float of 635,230,000 shares. How does Genmab A/S's short interest compare to its competitors? 0.22% of Genmab A/S's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Genmab A/S: Takeda Pharmaceutical Company Limited (0.15%), argenx SE (3.26%), BioNTech SE (1.06%), Teva Pharmaceutical Industries Limited (2.39%), BeiGene, Ltd. (1.41%), Viatris Inc. (2.96%), Intra-Cellular Therapies, Inc. (1.87%), Moderna, Inc. (11.03%), Summit Therapeutics Inc. (2.70%), Dr. Reddy's Laboratories Limited (1.57%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.83 billion), Charter Communications, Inc. ($3.77 billion), Reddit, Inc. ($2.98 billion), The Kroger Co. ($2.97 billion), International Paper ($2.64 billion), SoFi Technologies, Inc. ($1.99 billion), Rivian Automotive, Inc. ($1.93 billion), Onsemi ($1.81 billion), SoundHound AI, Inc. ($1.59 billion), and Moderna, Inc. ($1.57 billion). View all of the most shorted stocks. What does it mean to sell short Genmab A/S stock? Short selling GMAB is an investing strategy that aims to generate trading profit from Genmab A/S as its price is falling. GMAB shares are trading down $0.39 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Genmab A/S? A short squeeze for Genmab A/S occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GMAB, which in turn drives the price of the stock up even further. How often is Genmab A/S's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GMAB, twice per month. The most recent reporting period available is December, 31 2024. More Short Interest Resources from MarketBeat Related Companies TAK Short Interest ARGX Short Interest BNTX Short Interest TEVA Short Interest BGNE Short Interest VTRS Short Interest ITCI Short Interest MRNA Short Interest SMMT Short Interest RDY Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GMAB) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
